• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

EndoWays LTD, Developer of the First Disposable Robot for the Cathlab, Acquired by Ascendum

Share:

February 16, 2021

EndoWays, developer of a disposable robotic system for the cathlab, today announced the completion of an acquisition of a majority of its shares by Ascendum at an undisclosed cash amount.

EndoWays, which was founded in 2018 by Noam Shamay, Tovy Sivan and Tamir Ben David, is a portfolio company of MEDX Xelerator. During its incubation time, EndoWays developed a first-of-its-kind, fully disposable robotic system to support navigation and operation within blood vessels in neurovascular, peripheral and cardiac procedures. The deal will provide EndoWays with access to the vast experience and network of the Ascendum team, helping accelerate its clinical and commercial development, especially in China.

“Our vision is to provide an easy to use and cost-effective tool for the cathlab that will facilitate difficult procedures and allow physicians to work accurately through tortuous blood vessels away from radiation,” said Noam Shamay, EndoWays’ founder and CEO. “With the support of Ascendum’s experience and resources we can continue to make this vision a reality.” Shamay will serve as the company’s chief technology officer post acquisition.

“EndoWays was our very first incubator portfolio company, making its acquisition after less than three years since its founding, a significant milestone,” said Shai Policker, CEO of MEDX Xelerator. “We are proud of the achievements of the team and look forward to the company’s continued success.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“EndoWays provides attractive competitive advantages that can accelerate entry of robotics into the cathlab, which we believe will be highly valuable to future clinical practice,” explained Ms. Serena Shao, Founder and Managing Partner from Ascendum. “After the closing, Endoways is going to move into the incubator of our strategic partner, DiNovA Medtech, based in Israel, to continue development until commercial launch.”

Prof. Chaim Lotan, who will step in as EndoWays’ Chief Medical Officer added, “The unique features of this robot can help navigate through torturous pathways and enable complex procedures. This, together with the reduced radiation exposure for the user through use of this system, makes this technology very attractive to interventional radiologists and cardiologists.”

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Sanofi in $50m oncology collaborationSanofi in $50m oncology collaboration
  • Catalent to Acquire Leading Cell Therapy Company Masthercell Global for $315 Million, Creating An Industry-leading Cell & Gene Therapy PlatformCatalent to Acquire Leading Cell Therapy Company Masthercell Global for $315 Million, Creating An Industry-leading Cell & Gene Therapy Platform
  • Lonza Snaps up Drug Production Facility From NovartisLonza Snaps up Drug Production Facility From Novartis
  • J.P. Morgan Healthcare Conference kicks off Monday with focus on Trump, AmazonJ.P. Morgan Healthcare Conference kicks off Monday with focus on Trump, Amazon
  • Mirati and Sanofi Unite on Trial for KRAS InhibitorMirati and Sanofi Unite on Trial for KRAS Inhibitor
  • AstraZeneca to Sell US Rights of Lung Infection Drug to SobiAstraZeneca to Sell US Rights of Lung Infection Drug to Sobi
  • CTMS Provider Velos Joins WCGCTMS Provider Velos Joins WCG
  • Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 BillionKymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications